



Maharashtra Government  
Health Department

Medical Superintendent, Regional Referral Services Hospital,  
(Daffrin Hospital Campus), Shrikrushana Peth, Amravati-444601

Ph.No. 0721-2970161,  
0721-2970167.

Outward no./RRSH,Amt./MOU / 3844 /2022  
Date. 99/६/2022 Email : [msrrshamt@gmail.com](mailto:msrrshamt@gmail.com)

To,  
Rohera Healthcare & Technologies Pvt Ltd  
E-Medica  
Pune.

In Regional Referral Services Hospital, Amravati the installation & inauguration of E-Medica device was done in the month of February 2022, since that time patients were enrolled of different diseases as per instructions given by experts of E-Medica.

Total of 132 Covid confirmed cases were enrolled & studied for their improvement in health during this study period. About 60 minutes sessions were given on respective described mode of E-Medica device & parameters like SPO2, Pulse, Temperature, Blood pressure were noted for three different settings.

A total 110 already diagnosed hypertensive patients & 153 diagnosed type II Diabetes mellitus patients were enrolled in study to see the effect of device to minimize blood pressure & blood sugar respectively.

Individual values of baseline (i.e. before use of device) & also values after the use of device on day one, day two & day three were noted in Microsoft excel. Mean and standard deviation were calculated & 't' test were applied using open epi software. After applying 't' test of significance, 'p' value less than 0.05 at 95% confidence interval was considered statistically significant.

From the study conducted in this hospital it was concluded that, use of E-Medica device in covid-19 positive patients is a potent adjuvant to reduce the body temperature, pulse rate & improve the oxygen saturation levels in very short continuance of its utility. Also E-Medica device can be adjuvant to decrease the blood pressure & Blood sugar level in diagnosed hypertensive & diabetic patients.

Above results are due to following reasons as stated in Information Brochure given by the manufacturer of E-Medica-

“After applying eMedica device on the specific program (*as pre-programmed & fed in the device*), with specified frequency, voltage & current, it will Enhance the Cell charge of the organ. This process Improves the function of the Organ, Reduces Blood-Fat, Reduces the chances of Cardiac Arrest, Improves the Blood Circulation. When a mild current is exposed to virus or bacteria it would destroy the Virus & Bacteria in the body. In diabetic patients eMedica device transmits specific Voltages and Frequency with the specific electric charge into the human body. As this 3-dimensional technology passed through the blood stream, it enhances the charge of the  $\beta$ -cell in the pancreas, which in-turn improves the function of the organ helping it to produce more insulin. As a specific combination of Voltages-Frequency-Current is passed through the blood stream, it burns the fat/deposit/plaque from the blood vessel. This allows the

insulin generated from the ( $\beta$ -cell) pancreas to penetrate into the blood cells. As the natural insulin (*produced by  $\beta$ -cell*) reached the blood stream it immediately balances the Blood Sugar Level. Hence controlling Diabetes.” (Reference- [www.emedica.in](http://www.emedica.in), Rohera Healthcare & Technology Private Limited

ROHERA INC.)

This present pilot study was conducted on a limited sample size, which proved the efficacy on covid positive & hypertensive patients. Currently the study is being in process in large number of groups to see its results on Diabetic & hypertensive Patients. The long term effect of e- medica <sup>Needs to be</sup> is conducted on Diabetic patients to understand better blood sugar control over a long term use. As soon we achieve our desired sample size, we will publish its results.

Detailed results of this study with mean with standard deviation & P value are enclosed with this.

1. Dr. M. R. Mendhe – OSD, RRSB, Amravati.
2. Dr. G. Khobragade – MO, RRSB, Amravati.
3. Dr. Ravi Bushan – Nodal Officer RRSB-Covid, Amravati
4. Dr. V. S. Pawar – MO, RRSB, Amravati.
5. Dr. V. S. Dhande- MO, TBH, Amravati.
6. Dr. Shyam Gawande- MO, RRSB, Amravati

  
Medical Superintendent  
RRSB, Amravati  
Medical Superintendent  
Regional Referral Services Hospital  
AMRAVATI.

## COVID-19

**Table No.1: Effect of Emedica device on temperature in covid 19 positive patients (n=132)**

DAY	TEMPERATURE (Mean with SD)		P Value (t test)
	BEFORE	AFTER	
DAY 1	99.99 ± 0.98	97.20 ± 0.88	<0.0000001
DAY 2	99.56 ± 0.64	97.25 ± 0.94	<0.0000001
DAY 3	99.56 ± 0.51	97.61 ± 0.76	<0.0000001

**Table No.2: Effect of Emedica device on oxygen saturation in covid 19 positive patients**

DAY	SPO2 (Mean with SD)		P Value (t test)
	BEFORE	AFTER	
DAY 1	93.12 ± 1.52	96.15 ± 1.19	<0.0000001
DAY 2	94.94 ± 2.68	97.06 ± 1.64	<0.0000001
DAY 3	94.78 ± 2.24	97.48 ± 1.30	<0.0000001

**Table No.3: Effect of Emedica device on pulse rate in covid 19 positive patients**

DAY	PULSE (Mean with SD)		P Value (t test)
	BEFORE	AFTER	
DAY 1	92.09 ± 5.76	84.28 ± 12.51	<0.0000001
DAY 2	94.68 ± 4.91	89.27 ± 7.42	<0.0000001
DAY 3	96.12 ± 4.48	90.53 ± 5.73	<0.0000001

Total 132 covid positive patients were enrolled in research to study the effect of Emedica device on improvement in health status of patients. It was found that mean temperature of covid positive patients get decreases, after a session of 60 minutes duration in a day, also it was found that mean temperature of patients were decreases subsequently on day 2 & 3 after its use and the difference was statistically significant. (P <0.05).

Similarly, one of the crucial parameter in covid patients i.e. oxygen saturation shows drastic increase in SPO2 & the difference was statistically significant. ( $P < 0.05$ ) Mean pulse was also reduced subsequently after the use of Emedica device, & difference was also statistically significant.

Thus, it can be concluded that, use of Emedica devise in covid 19 positive patients can be a potent adjuvant to reduce the body temperature, pulse rate & improve the oxygen saturation in very short continuance of its utility.

## BLOOD PRESSURE

**Table No.4: Effect of Emedica device on systolic blood pressure in diagnosed case of hypertension (n=110)**

DAY	SYSTOLIC BLOOD PRESSURE (Mean with SD)		P Value (t test)
	BEFORE	AFTER	
DAY 1	147.73 ± 15.63	125.93 ± 16.45	<0.0000001
DAY 2	139.70 ± 11.55	131.5 ± 13.52	0.000002496
DAY 3	143.30 ± 9.12	133.94 ± 9.73	<0.0000001

**Table No.5: Effect of Emedica device on diastolic blood pressure in diagnosed case of hypertension**

DAY	DIASTOLIC BLOOD PRESSURE (Mean with SD)		P Value (t test)
	BEFORE	AFTER	
DAY 1	90.21 ± 9.87	88.85 ± 13.70	0.3992
DAY 2	84.71 ± 8.00	74.77 ± 6.89	<0.0000001
DAY 3	86.72 ± 7.86	82.68 ± 7.70	0.0001547

Total 110 diagnosed cases of Hypertension were studied to see the effect of Emedica device on its effect on lowering blood pressure. It was found that both systolic and diastolic blood pressure get decreases after the use of Emedica device. Also the difference was statistically significant. (P < 0.05)

## RANDOM BLOOD SUGAR

**Table No.6: Effect of Emedica device on random blood sugar in diagnosed case of diabetes mellitus. (n=153)**

DAY	RANDOM BLOOD SUGAR (Mean with SD)		P Value (t test)
	BEFORE	AFTER	
DAY 1	197.16±20.00	136.84 ± 16.92	<0.0000001
DAY 2	185.19 ± 19.75	135.17 ± 16.23	<0.0000001
DAY 3	172.90 ± 21.55	126.56 ± 15.58	<0.0000001

Total 153 diagnosed cases of Diabetes mellitus type 2 were studied for the effect of Emedica device on blood sugar level & it was found that after a session of Emedica device random blood glucose level get decreases and the difference was statistically significant. (P <0.05)